CANbridge Pharmaceuticals Future Growth

Future criteria checks 2/6

CANbridge Pharmaceuticals is forecast to grow earnings and revenue by 10.4% and 37.6% per annum respectively. EPS is expected to grow by 10.4% per annum. Return on equity is forecast to be -38.7% in 3 years.

Key information

10.4%

Earnings growth rate

10.4%

EPS growth rate

Biotechs earnings growth	35.8%
Revenue growth rate	37.6%
Future return on equity	-38.7%
Analyst coverage	Low
Last updated	07 May 2024

Recent future growth updates

Recent updates

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Apr 23

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

May 05

Earnings and Revenue Growth Forecasts

SEHK:1228 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	300	-284	N/A	N/A	1
12/31/2025	274	-293	N/A	N/A	2
12/31/2024	133	-308	N/A	N/A	2
12/31/2023	103	-379	N/A	N/A	N/A
9/30/2023	95	-416	N/A	N/A	N/A
6/30/2023	87	-453	-314	-304	N/A
3/31/2023	83	-468	-305	-292	N/A
12/31/2022	79	-483	-296	-281	N/A
9/30/2022	66	-733	-340	-327	N/A
6/30/2022	54	-982	-384	-373	N/A
3/31/2022	42	-1,089	-599	-591	N/A
12/31/2021	31	-1,077	-461	-587	N/A
9/30/2021	27	-1,055	-391	-515	N/A
6/30/2021	22	-1,034	-321	-443	N/A
3/31/2021	18	-828	-218	-196	N/A
12/31/2020	12	-846	-305	-152	N/A
12/31/2019	1	-218	-169	-126	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1228 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1228 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1228 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1228's revenue (37.6% per year) is forecast to grow faster than the Hong Kong market (8% per year).

High Growth Revenue: 1228's revenue (37.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1228 is forecast to be unprofitable in 3 years.

CANbridge Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 23%

Price target decreased by 21% to HK$7.00

Consensus EPS estimates upgraded to CN¥0.59 loss

Price target decreased by 82% to HK$1.70

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus EPS estimates upgraded to CN¥1.05 loss

Recent updates

Consensus EPS estimates fall by 23%

Price target decreased by 21% to HK$7.00

Consensus EPS estimates upgraded to CN¥0.59 loss

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee

CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress

CANbridge Announces NDA Acceptance of CAN108 (???®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration

Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China

Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Algs)

First half 2023 earnings released: CN¥0.51 loss per share (vs CN¥0.59 loss in 1H 2022)

CANbridge Pharmaceuticals Inc. to Report First Half, 2023 Results on Aug 30, 2023

Price target decreased by 82% to HK$1.70

Consensus revenue estimates decrease by 22%, EPS upgraded

New minor risk - Share price stability

CANbridge Pharmaceuticals Inc. Announces Preliminary Clinical Data of Phase 1B Study of Omoprubart (CAN106) in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Consensus EPS estimates upgraded to CN¥1.05 loss

CANbridge Pharmaceuticals, Inc. Announces Marketing Approval of CAN108 (LIVMARLI) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

CANbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in China Region of the Global LIVMARLI(R) (CAN108) EMBARK Phase 2 Study in Biliary Atresia

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China

High number of new and inexperienced directors

First half 2022 earnings released: CN¥0.59 loss per share (vs CN¥46.79 loss in 1H 2021)

CANbridge Pharmaceuticals Inc. to Report First Half, 2022 Results on Aug 24, 2022

Canbridge Pharmaceuticals Inc. Announces First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China

CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board

Canbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Announces Results from its CAN106 Phase 1 Trial

CANbridge Pharmaceuticals Inc. Appoints Pauline Li as Senior Vice President of Clinical Development and Operations

High number of new and inexperienced directors

CANbridge Pharmaceuticals Inc. Announces Executive Changes

CANbridge Pharmaceuticals Inc. Announces First Patient Has Been Dosed in the Can106 Phase 1B/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria in China

Canbridge Pharmaceuticals Inc. Announces Approval of Can108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone

CANbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Reports Positive Top-Line Can106 Phase 1 Data

CANbridge Pharmaceuticals CAN108 New Drug Application (NDA) for Alagille Syndrome Accepted by China’s National Medical Products Administration

CANbridge Pharmaceuticals Inc. has completed an IPO in the amount of HKD 685.13718 million.

Less than half of directors are independent

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies